Loss of type III transforming growth factor-Β receptor expression is due to methylation silencing of the transcription factor GATA3 in renal cell carcinoma

S. J. Cooper, H. Zou, S. N. Legrand, L. A. Marlow, C. A. Von Roemeling, D. C. Radisky, K. J. Wu, Nadine Hempel, V. Margulis, H. W. Tun, G. C. Blobe, C. G. Wood, J. A. Copland

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Loss of transforming growth factor-Β receptor III (TΒRIII) correlates with loss of transforming growth factor-Β (TGF-Β) responsiveness and suggests a role for dysregulated TGF-Β signaling in clear cell renal cell carcinoma (ccRCC) progression and metastasis. Here we identify that for all stages of ccRCC TΒRIII expression is downregulated in patient-matched tissue samples and cell lines. We find that this loss of expression is not due to methylation of the gene and we define GATA3 as the first transcriptional factor to positively regulate TΒRIII expression in human cells. We localize GATA3′s binding to a 10-bp region of the TΒRIII proximal promoter. We demonstrate that GATA3 mRNA is downregulated in all stages, of ccRCC, mechanistically show that GATA3 is methylated in ccRCC patient tumor tissues as well as cell lines, and that inhibiting GATA3 expression in normal renal epithelial cells downregulates TΒRIII mRNA and protein expression. These data support a sequential model whereby loss of GATA3 expression through epigenetic silencing decreases TΒRIII expression during ccRCC progression.

Original languageEnglish (US)
Pages (from-to)2905-2915
Number of pages11
JournalOncogene
Volume29
Issue number20
DOIs
StatePublished - May 20 2010

Fingerprint

GATA3 Transcription Factor
Growth Factor Receptors
Transforming Growth Factors
Renal Cell Carcinoma
Methylation
Naphazoline
Down-Regulation
Cell Line
Messenger RNA
Epigenomics
Epithelial Cells
Neoplasm Metastasis
Kidney
Genes

All Science Journal Classification (ASJC) codes

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Cooper, S. J., Zou, H., Legrand, S. N., Marlow, L. A., Von Roemeling, C. A., Radisky, D. C., ... Copland, J. A. (2010). Loss of type III transforming growth factor-Β receptor expression is due to methylation silencing of the transcription factor GATA3 in renal cell carcinoma. Oncogene, 29(20), 2905-2915. https://doi.org/10.1038/onc.2010.64
Cooper, S. J. ; Zou, H. ; Legrand, S. N. ; Marlow, L. A. ; Von Roemeling, C. A. ; Radisky, D. C. ; Wu, K. J. ; Hempel, Nadine ; Margulis, V. ; Tun, H. W. ; Blobe, G. C. ; Wood, C. G. ; Copland, J. A. / Loss of type III transforming growth factor-Β receptor expression is due to methylation silencing of the transcription factor GATA3 in renal cell carcinoma. In: Oncogene. 2010 ; Vol. 29, No. 20. pp. 2905-2915.
@article{96c9b850b68c4299b3805d272ca2e63e,
title = "Loss of type III transforming growth factor-Β receptor expression is due to methylation silencing of the transcription factor GATA3 in renal cell carcinoma",
abstract = "Loss of transforming growth factor-Β receptor III (TΒRIII) correlates with loss of transforming growth factor-Β (TGF-Β) responsiveness and suggests a role for dysregulated TGF-Β signaling in clear cell renal cell carcinoma (ccRCC) progression and metastasis. Here we identify that for all stages of ccRCC TΒRIII expression is downregulated in patient-matched tissue samples and cell lines. We find that this loss of expression is not due to methylation of the gene and we define GATA3 as the first transcriptional factor to positively regulate TΒRIII expression in human cells. We localize GATA3′s binding to a 10-bp region of the TΒRIII proximal promoter. We demonstrate that GATA3 mRNA is downregulated in all stages, of ccRCC, mechanistically show that GATA3 is methylated in ccRCC patient tumor tissues as well as cell lines, and that inhibiting GATA3 expression in normal renal epithelial cells downregulates TΒRIII mRNA and protein expression. These data support a sequential model whereby loss of GATA3 expression through epigenetic silencing decreases TΒRIII expression during ccRCC progression.",
author = "Cooper, {S. J.} and H. Zou and Legrand, {S. N.} and Marlow, {L. A.} and {Von Roemeling}, {C. A.} and Radisky, {D. C.} and Wu, {K. J.} and Nadine Hempel and V. Margulis and Tun, {H. W.} and Blobe, {G. C.} and Wood, {C. G.} and Copland, {J. A.}",
year = "2010",
month = "5",
day = "20",
doi = "10.1038/onc.2010.64",
language = "English (US)",
volume = "29",
pages = "2905--2915",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "20",

}

Cooper, SJ, Zou, H, Legrand, SN, Marlow, LA, Von Roemeling, CA, Radisky, DC, Wu, KJ, Hempel, N, Margulis, V, Tun, HW, Blobe, GC, Wood, CG & Copland, JA 2010, 'Loss of type III transforming growth factor-Β receptor expression is due to methylation silencing of the transcription factor GATA3 in renal cell carcinoma', Oncogene, vol. 29, no. 20, pp. 2905-2915. https://doi.org/10.1038/onc.2010.64

Loss of type III transforming growth factor-Β receptor expression is due to methylation silencing of the transcription factor GATA3 in renal cell carcinoma. / Cooper, S. J.; Zou, H.; Legrand, S. N.; Marlow, L. A.; Von Roemeling, C. A.; Radisky, D. C.; Wu, K. J.; Hempel, Nadine; Margulis, V.; Tun, H. W.; Blobe, G. C.; Wood, C. G.; Copland, J. A.

In: Oncogene, Vol. 29, No. 20, 20.05.2010, p. 2905-2915.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Loss of type III transforming growth factor-Β receptor expression is due to methylation silencing of the transcription factor GATA3 in renal cell carcinoma

AU - Cooper, S. J.

AU - Zou, H.

AU - Legrand, S. N.

AU - Marlow, L. A.

AU - Von Roemeling, C. A.

AU - Radisky, D. C.

AU - Wu, K. J.

AU - Hempel, Nadine

AU - Margulis, V.

AU - Tun, H. W.

AU - Blobe, G. C.

AU - Wood, C. G.

AU - Copland, J. A.

PY - 2010/5/20

Y1 - 2010/5/20

N2 - Loss of transforming growth factor-Β receptor III (TΒRIII) correlates with loss of transforming growth factor-Β (TGF-Β) responsiveness and suggests a role for dysregulated TGF-Β signaling in clear cell renal cell carcinoma (ccRCC) progression and metastasis. Here we identify that for all stages of ccRCC TΒRIII expression is downregulated in patient-matched tissue samples and cell lines. We find that this loss of expression is not due to methylation of the gene and we define GATA3 as the first transcriptional factor to positively regulate TΒRIII expression in human cells. We localize GATA3′s binding to a 10-bp region of the TΒRIII proximal promoter. We demonstrate that GATA3 mRNA is downregulated in all stages, of ccRCC, mechanistically show that GATA3 is methylated in ccRCC patient tumor tissues as well as cell lines, and that inhibiting GATA3 expression in normal renal epithelial cells downregulates TΒRIII mRNA and protein expression. These data support a sequential model whereby loss of GATA3 expression through epigenetic silencing decreases TΒRIII expression during ccRCC progression.

AB - Loss of transforming growth factor-Β receptor III (TΒRIII) correlates with loss of transforming growth factor-Β (TGF-Β) responsiveness and suggests a role for dysregulated TGF-Β signaling in clear cell renal cell carcinoma (ccRCC) progression and metastasis. Here we identify that for all stages of ccRCC TΒRIII expression is downregulated in patient-matched tissue samples and cell lines. We find that this loss of expression is not due to methylation of the gene and we define GATA3 as the first transcriptional factor to positively regulate TΒRIII expression in human cells. We localize GATA3′s binding to a 10-bp region of the TΒRIII proximal promoter. We demonstrate that GATA3 mRNA is downregulated in all stages, of ccRCC, mechanistically show that GATA3 is methylated in ccRCC patient tumor tissues as well as cell lines, and that inhibiting GATA3 expression in normal renal epithelial cells downregulates TΒRIII mRNA and protein expression. These data support a sequential model whereby loss of GATA3 expression through epigenetic silencing decreases TΒRIII expression during ccRCC progression.

UR - http://www.scopus.com/inward/record.url?scp=77952675064&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952675064&partnerID=8YFLogxK

U2 - 10.1038/onc.2010.64

DO - 10.1038/onc.2010.64

M3 - Article

C2 - 20208565

AN - SCOPUS:77952675064

VL - 29

SP - 2905

EP - 2915

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 20

ER -